Literature DB >> 27495776

Conformational Variants of the Individual HLA-I Antigens on Luminex Single Antigen Beads Used in Monitoring HLA Antibodies: Problems and Solutions.

Vadim Jucaud1, Mepur H Ravindranath, Paul I Terasaki.   

Abstract

BACKGROUND: Single antigen beads (SAB) are used for monitoring HLA antibodies in pretransplant and posttransplant patients despite the discrepancy between virtual and actual crossmatch results and transplant outcomes. This discrepancy can be attributed to the presence of conformational variants of HLA-I on SAB, assessment of which would increase the concordance between SAB and flow cytometry crossmatch (FCXM) results, thus enabling improved organ accessibility for the waiting list patients and a better prediction of antibody-mediated rejection.
METHODS: The conformational variants were examined on HLA-I beads, iBeads, acid-/alkali-treated beads, and T cells using HLA-I monoclonal antibodies (W6/32, TFL-006, and heavy chain (HC)-10).
RESULTS: The affinity of the monoclonal antibodies against HLA-I beads confirmed the presence and heterogeneous density of peptide-associated β2-microglobulin-associated HLA HC (pepA-β2aHC), peptide-free-β2aHC (pepF-β2aHC), and β2-free HC (β2fHC) on every single antigen-coated bead. In contrast, iBeads harbor a high density of pepA-β2aHC, low density of pepF-β2aHC, and are lacking β2fHC. The FCXM analyses confirmed the prevalence of pepA-β2aHC, but not pepF-β2aHC or β2fHC on resting T cells.
CONCLUSIONS: The strength of a donor-specific antibody should be assessed with a bead-specific mean fluorescence intensity cutoff based on TFL-006 reactivity against HLA-I beads, and HC-10 against iBeads, where the β2fHC or pepF-β2aHC normalized donor-specific antibody level would reveal the true anti-pepA-β2aHC reactivity associated with positive FCXM.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 27495776      PMCID: PMC7228605          DOI: 10.1097/TP.0000000000001420

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  44 in total

1.  Clinically irrelevant circulating human leukocyte antigen antibodies in the presence of ventricular assist devices.

Authors:  Afzal Nikaein; Nadim El-Awar; Judson Hunt; Edward J Rosenthal; Eric Eichhorn; Shelly Hall; James Boehrer; Mitchell Magee; Marc Pieniek; William Brinkman; Todd Dewey
Journal:  J Heart Lung Transplant       Date:  2011-11-10       Impact factor: 10.247

2.  Impact of peptides on the recognition of HLA class I molecules by human HLA antibodies.

Authors:  Arend Mulder; Chantal Eijsink; Michel G D Kester; Marry E I Franke; Marrie J Kardol; Mirjam H M Heemskerk; Cees van Kooten; Frank A Verreck; Jan Wouter Drijfhout; Frits Koning; Ilias I N Doxiadis; Frans H J Claas
Journal:  J Immunol       Date:  2005-11-01       Impact factor: 5.422

3.  Nebulous humors: defining alloantibodies in the 21st century.

Authors:  Paul Warner
Journal:  Hum Immunol       Date:  2009-04-15       Impact factor: 2.850

4.  Peptide modulation of class I major histocompatibility complex protein molecular flexibility and the implications for immune recognition.

Authors:  William F Hawse; Brian E Gloor; Cory M Ayres; Kevin Kho; Elizabeth Nuter; Brian M Baker
Journal:  J Biol Chem       Date:  2013-07-08       Impact factor: 5.157

5.  Invariant chain association with MHC class I: preference for HLA class I/beta 2-microglobulin heterodimers, specificity, and influence of the MHC peptide-binding groove.

Authors:  J L Vigna; K D Smith; C T Lutz
Journal:  J Immunol       Date:  1996-11-15       Impact factor: 5.422

6.  Positive virtual crossmatch with negative flow crossmatch results in two cases.

Authors:  Eapen K Jacob; Steve R De Goey; Manish J Gandhi
Journal:  Transpl Immunol       Date:  2011-05-23       Impact factor: 1.708

7.  Donor-specific antibody against denatured HLA-A1: clinically nonsignificant?

Authors:  Shalini Pereira; Susan Perkins; Jar-How Lee; Wayne Shumway; William LeFor; Mayra Lopez-Cepero; Cynthia Wong; Amy Connolly; Jane C Tan; F Carl Grumet
Journal:  Hum Immunol       Date:  2011-03-09       Impact factor: 2.850

8.  "Natural" human leukocyte antigen antibodies found in nonalloimmunized healthy males.

Authors:  Luis E Morales-Buenrostro; Paul I Terasaki; Lluvia A Marino-Vázquez; Jar-How Lee; Nadim El-Awar; Josefina Alberú
Journal:  Transplantation       Date:  2008-10-27       Impact factor: 4.939

9.  Influence of test technique on sensitization status of patients on the kidney transplant waiting list.

Authors:  P Gombos; G Opelz; S Scherer; C Morath; M Zeier; P Schemmer; C Süsal
Journal:  Am J Transplant       Date:  2013-07-10       Impact factor: 8.086

10.  Interaction pattern of Arg 62 in the A-pocket of differentially disease-associated HLA-B27 subtypes suggests distinct TCR binding modes.

Authors:  Elisa Nurzia; Daniele Narzi; Alberto Cauli; Alessandro Mathieu; Valentina Tedeschi; Silvana Caristi; Rosa Sorrentino; Rainer A Böckmann; Maria Teresa Fiorillo
Journal:  PLoS One       Date:  2012-03-05       Impact factor: 3.240

View more
  14 in total

1.  The Authors' Reply.

Authors:  Mepur H Ravindranath; Vadim Jucaud
Journal:  Transplantation       Date:  2017-04       Impact factor: 4.939

2.  Conformational Variants of HLA-I Antigens on Luminex Single Antigen Beads.

Authors:  Jonathan Visentin; Gwendaline Guidicelli; Jean-Luc Taupin
Journal:  Transplantation       Date:  2017-04       Impact factor: 4.939

3.  Significance of the intraindividual variability of HLA IgG antibodies in renal disease patients observed with different beadsets monitored with two different secondary antibodies on a Luminex platform.

Authors:  Mepur H Ravindranath; Edward J Filippone; Grace Mahowald; Carly Callender; Adarsh Babu; Susan Saidman; Soldano Ferrone
Journal:  Immunol Res       Date:  2018-10       Impact factor: 2.829

4.  Monitoring native HLA-I trimer specific antibodies in Luminex multiplex single antigen bead assay: Evaluation of beadsets from different manufacturers.

Authors:  Mepur H Ravindranath; Vadim Jucaud; Soldano Ferrone
Journal:  J Immunol Methods       Date:  2017-08-04       Impact factor: 2.303

Review 5.  HLA Class Ia and Ib Polyreactive Anti-HLA-E IgG2a Monoclonal Antibodies (TFL-006 and TFL-007) Suppress Anti-HLA IgG Production by CD19+ B Cells and Proliferation of CD4+ T Cells While Upregulating Tregs.

Authors:  Mepur H Ravindranath
Journal:  J Immunol Res       Date:  2017-05-28       Impact factor: 4.818

6.  Comparison of Physical Crossmatch and Virtual Crossmatch to Identify Preexisting Donor-Specific Human Leukocyte Antigen (HLA) Antibodies and Outcome Following Kidney Transplantation.

Authors:  Bo Peng; Quan Zhuang; Meng Yu; Junhui Li; Yun Liu; Lijun Zhu; Yingzi Ming
Journal:  Med Sci Monit       Date:  2019-02-03

7.  Peptides Derived From Mismatched Paternal Human Leukocyte Antigen Predicted to Be Presented by HLA-DRB1, -DRB3/4/5, -DQ, and -DP Induce Child-Specific Antibodies in Pregnant Women.

Authors:  Matthias Niemann; Benedict M Matern; Eric Spierings; Stefan Schaub; Gideon Hönger
Journal:  Front Immunol       Date:  2021-12-21       Impact factor: 7.561

Review 8.  Four Faces of Cell-Surface HLA Class-I: Their Antigenic and Immunogenic Divergence Generating Novel Targets for Vaccines.

Authors:  Mepur H Ravindranath; Narendranath M Ravindranath; Senthamil R Selvan; Edward J Filippone; Carly J Amato-Menker; Fatiha El Hilali
Journal:  Vaccines (Basel)       Date:  2022-02-21

Review 9.  Therapeutic Potential of HLA-I Polyreactive mAbs Mimicking the HLA-I Polyreactivity and Immunoregulatory Functions of IVIg.

Authors:  Mepur H Ravindranath; Fatiha El Hilali; Edward J Filippone
Journal:  Vaccines (Basel)       Date:  2021-06-21

10.  Defining the structural basis for human leukocyte antigen reactivity in clinical transplantation.

Authors:  Yue Gu; Robynne W K Koh; May Ling Lai; Denise Pochinco; Rachel Z C Teo; Marieta Chan; Tanusya M Murali; Chong Wai Liew; Yee Hwa Wong; Nicholas R J Gascoigne; Kathryn J Wood; Julien Lescar; Peter Nickerson; Paul A MacAry; Anantharaman Vathsala
Journal:  Sci Rep       Date:  2020-10-27       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.